PODS: Polyhedrin and sustained release

Polyhedrin is one of nature's most abundant proteins. Without realising it, we may be regularly eating it, and yet most molecular biologists encounter it only as a footnote in insect virology textbooks. It originates from baculoviruses, a family of insect pathogens that have co-evolved with their hosts for millions of years. The virus produces polyhedrin crystals to protect its progeny during the harsh journey through insect digestive tracts and the environment, packaging viral particles in a mineralised cage of pure protein. Cell Guidance Systems has repurposed this ancient mechanism for a contemporary problem: delivering growth factors to tissue and cell culture with sustained, tunable kinetics that match the timescale of tissue repair and regeneration.

This article explains the biology of polyhedrin, how it functions as a viral survival strategy, and how the PODS' (Polyhedrin Delivery System) mechanism harnesses polyhedrin's crystalline architecture to encapsulate growth factors and control their release over days to weeks. The result is a platform that achieves therapeutic effect at lower total doses, reduces systemic exposure, and integrates more naturally into tissue remodelling workflows than conventional bolus injection or synthetic polymer depots.

Polyhedrin in Nature: The Baculovirus Strategy

Baculoviruses are large, double-stranded DNA viruses that infect insects and other arthropods. Lepidoptera (butterflies and moths) and Hymenoptera (sawflies) are the primary hosts, but the virus family encompasses a wider range of invertebrate pathogens. The virus replicates within host nuclei, and in the late stages of infection, virions begin to accumulate in crystalline inclusions within the nucleus. These inclusions, called polyhedra (singular: polyhedron), are composed almost entirely of a single protein: polyhedrin.

Polyhedrin is expressed at extremely high levels late in infection, becoming up to 50% of total cellular protein in heavily infected cells. It assembles spontaneously into a rigid, geometric lattice around nascent virions. A single infected cell can produce hundreds of thousands of polyhedra, each one micrometres across and containing hundreds of viral particles embedded within the crystalline matrix. The polyhedra are extremely resistant to environmental damage, heat, UV radiation, desiccation and the acidic environment of insect digestive tracts.

The adaptive logic is evident: when the infected insect excretes or dies, the polyhedra survive intact in the harsh external environment. The rigid crystal structure physically protects the viral particles from enzymatic degradation and exposure. When another susceptible insect ingests the contaminated food or water, the polyhedra dissolve in the slightly alkaline environment of the midgut, releasing infectious virions that initiate a new round of infection. From the virus's perspective, polyhedrin is not metabolically expensive structural waste: it is a sophisticated, environment-responsive delivery vehicle that ensures transmission to the next host.

Polyhedrin Structure and Crystal Architecture

X-ray crystallography has revealed the atomic structure of polyhedrin and its lattice arrangement. Polyhedrin is a globular protein of approximately 29 to 30 kDa, with an oblate or disc-like shape. It lacks enzymatic activity and its primary function is purely structural. The protein folds into a compact domain with a high proportion of beta-sheet secondary structure, giving it rigidity and resistance to proteolytic degradation.

Individual polyhedrin molecules assemble into a cubic or tetragonal crystal lattice depending on the virus species and assembly conditions. The lattice is held together by protein-protein interactions across multiple interfaces, not by covalent crosslinks or post-translational modifications. The crystal is hydrated, with water molecules occupying channels and cavities throughout the matrix. This hydration is critical: it allows for the gradual exchange of molecules at the crystal surface while maintaining structural integrity over weeks or months. The crystal is not a static, impermeable block of protein, but rather a permeable, dynamically equilibrating matrix.

The polyhedra that form within infected cells are typically 0.2 to 5 micrometers in diameter, although the size range varies with virus species. The crystalline structure is so regular that individual polyhedra often display geometric facets visible by light microscopy. The regularity of the lattice means that polyhedra prepared from different batches of virus-infected insects show consistent morphology and dissolution kinetics, an important property for manufacturing and quality control.

The PODS Mechanism: Encapsulation and Controlled Release

The PODS platform works by embedding growth factors into polyhedrin crystals during or immediately after crystal formation. The growth factor molecules are mixed with polyhedrin monomers under conditions that allow the crystal lattice to assemble around them, physically incorporating them into the matrix. The growth factors become trapped within the crystal interstices, held in place by the surrounding protein cage.

Release occurs as the polyhedrin crystal gradually dissolves in physiological conditions. The dissolution is not all-or-nothing: rather, the crystal surface erodes slowly, releasing encapsulated molecules as the lattice breaks down. The dissolution rate is controlled by several parameters that can be engineered into the system: the size and porosity of the crystal, the pH and osmolarity of the surrounding medium, the presence of proteolytic enzymes or crystal-binding factors in the local tissue environment, and the specific polyhedrin variant used (wild-type or engineered versions with altered solubility).

The key insight is that growth factors released from PODS are delivered at concentrations and timescales that match physiological repair responses. A typical PODS formulation might deliver nanogram to microgram quantities of growth factor per day over a 1 to 4 week period, compared to bolus injection which delivers the entire dose within hours and is rapidly cleared or sequestered. The sustained, low-concentration profile allows tissue to respond without saturation, receptor downregulation, or overwhelming systemic effects.

This is distinct from the action of native growth factors during wound healing or tissue remodelling. When tissue is injured, growth factors are released locally from platelets, extracellular matrix, and infiltrating immune cells. The local concentration rises over hours to days, triggering a cascade of cell recruitment, proliferation and differentiation. The concentration then declines gradually as the growth factors are internalized, degraded or sequestered. PODS mimics this natural temporal profile by delivering sustained, declining concentrations in the local microenvironment.

The Chemistry of Encapsulation

The mechanism by which growth factors become incorporated into polyhedrin crystals during assembly is not fully understood, and likely depends on the specific growth factor and polyhedrin variant in use. Indeed, the loading efficiency is cargo-dependent. Proposed mechanisms include passive diffusion of the growth factor into the growing crystal lattice (if the growth factor is small or flexible enough to fit within crystal interstices), adsorption to the polyhedrin surface during nucleation (with the growing crystal then encapsulating the bound protein), or specific interactions between the growth factor and polyhedrin that direct co-assembly.

Different polyhedrin variants can be engineered to favour different crystal polymorphs, controlling the pore size and dissolution rate of the resulting lattice. Wild-type polyhedrin from Bombyx mori (silkworm) baculovirus is the most studied, but related baculoviruses yield polyhedrins with distinct assembly kinetics and crystal properties.

Encapsulation efficiency varies depending on the growth factor and formulation: proteins that are more hydrophobic or have specific binding interactions with polyhedrin show higher incorporation than those with weak or no affinity. The growth factor does not need to be covalently modified or tagged to be retained; the physical containment of the crystal matrix is sufficient. However, the growth factor must remain folded and biologically active in the hydrated crystal environment. Most protein growth factors tolerate this without issue.

Dissolution Kinetics and Release Profiles

The in vitro dissolution of PODS crystals follows predictable kinetics that can be tuned by crystal design. When a PODS preparation is placed in dissolution medium (typically PBS or culture medium), the polyhedrin at the crystal surface begins to dissolve and any encapsulated growth factor diffusing out. The total amount of growth factor released increases roughly linearly with time over the first 1 to 2 weeks, then levels off as the crystal approaches complete dissolution.

The dissolution rate depends on several engineering parameters: (1) crystal size: larger crystals have lower surface-area-to-volume ratios and dissolve more slowly; (2) crystal porosity and water accessibility: engineering the polyhedrin lattice to be more open allows faster fluid penetration and faster dissolution; (3) ionic strength and pH of the surrounding medium: extreme pH or high salt can accelerate dissolution, while physiological pH and osmolarity represent a kind of "design point" for which PODS is tuned; (4) presence of proteases: tissue proteases can accelerate dissolution by directly cleaving polyhedrin, allowing faster release.

In tissue, dissolution kinetics are further modified by the local microenvironment. A PODS depot placed subcutaneously releases growth factors more slowly than the same preparation in vitro, because subcutaneous tissue is relatively avascular and the local osmolarity and pH may differ from standard culture conditions. A PODS depot placed in an actively inflamed wound bed releases faster because infiltrating macrophages and neutrophils produce proteases that digest the polyhedrin matrix. This environmental responsiveness is an advantage: the device automatically releases more growth factor where it is needed most (in the context of active tissue remodelling) and less where it is not needed (in quiescent tissue).

Advantages of PODS Over Alternative Delivery Systems

Versus bolus injection: Bolus injection delivers the entire dose within minutes, leading to supraphysiological peak concentrations that saturate receptors, trigger compensatory downregulation, and are rapidly cleared by the circulation. PODS delivers lower, sustained concentrations that maintain receptor sensitivity and match the kinetics of endogenous signalling. Lower total doses are required to achieve comparable tissue effect, reducing systemic exposure and off-target effects. The sustained delivery profile extends the therapeutic window, allowing a single administration to provide benefit over weeks rather than hours.

Versus synthetic polymer depots (PLGA, PCL): Synthetic polymers degrade by hydrolysis and enzymatic cleavage, releasing encapsulated drugs as the polymer erodes. They also suffer from burst release due to the accumulation of cargo at the surface due to surface tension effects. Release kinetics are difficult to predict and control because they depend on polymer crystallinity, molecular weight, water penetration rate, and local pH and enzyme activity. PODS crystals dissolve by surface erosion and are entirely proteinaceous, eliminating concerns about polymer degradation byproducts (lactic acid, glycolic acid) that can cause local inflammation. The dissolved polyhedrin is simply proteolysed to peptides and amino acids, the same as any dietary protein. PODS does not require organic solvents for manufacturing and is biocompatible by default.

Versus microencapsulation in liposomes: Liposomes are attractive for encapsulating hydrophobic molecules and for delivering precise doses to specific cell types (via targeting ligands), but they are not naturally stable in tissue and tend to fuse or leak within hours to days. PODS crystals are stable over weeks and do not leak unless they are actively dissolving. Liposomes require careful storage (typically at 4 C or as lyophilised cakes) and have limited shelf-life. PODS preparations are stable at room temperature for extended periods and can be lyophilised without loss of function.

Versus hydrogel depots (PeptiGel, alginate, hyaluronic acid): Hydrogels are porous networks that can encapsulate large molecules and provide sustained release. However, hydrogels are generally amorphous and release kinetics depend on pore size, crosslink density and the diffusion coefficient of the encapsulated molecule. Tuning release profiles requires changing gel composition, which can be laborious and unpredictable. PODS crystals have a defined, ordered lattice with well-characterised transport properties. Furthermore, hydrogels must be injectable or pre-formed, limiting their applicability. PODS crystals can be embedded in hydrogels (PODS-in-gel formulations) to provide the structural benefits of the gel with the precise release kinetics of the PODS crystal.

Comparing Growth Factor Delivery Systems

PODS in Clinical and Therapeutic Context

The therapeutic applications of PODS growth factors span regenerative medicine, wound healing, and tissue engineering. The platform has been tested in preclinical models of bone regeneration, soft tissue repair, skin wound healing, and inflammatory disease, with consistent evidence that sustained PODS-mediated delivery outperforms bolus dosing. 

The advantage of PODS in these settings is that tissue repair is inherently a multi-step, multi-week process. Wound healing involves sequential phases of haemostasis, inflammation, proliferation and remodelling, each lasting days to weeks. Growth factors are not useful as one-time bolus doses because the tissue is not ready to respond to them for the first few days after injury (the inflammatory phase), and continues to need them weeks later during the proliferation and remodelling phases. PODS crystals dissolve in parallel with the phases of wound healing, delivering growth factor when it is needed most and avoiding excessive early doses that would recruit leukocytes without productive tissue building.

In bone regeneration, PODS-delivered bone morphogenetic proteins (BMPs) or VEGF promote new bone formation with less total protein and fewer off-target effects than bolus BMP injection. Sustained VEGF delivery from PODS enhances angiogenesis in tissue engineering scaffolds, supporting cell survival in thicker 3D constructs. In skin wound healing, PODS-delivered fibroblast growth factor (FGF) or transforming growth factor (TGF) accelerates closure while reducing systemic inflammation and scar formation.

Manufacturing and Source Material: From Virus to Medicine

Polyhedrin for therapeutic use comes from two main sources: production in baculovirus-infected insect cells (the traditional route, still used for many applications), or recombinant expression in mammalian cells, bacteria, or yeast. The advantages and disadvantages of each source have implications for manufacturing, cost and regulatory pathway.

Baculovirus-infected insect cells. Polyhedra are produced naturally in large amounts (50% of total cellular protein) when insect cells (typically Spodoptera frugiperda cells) are infected with baculovirus. The cells are cultured in bioreactors, infected with virus, and polyhedra are harvested directly from the lysate by crude centrifugation (they settle as large aggregates). The polyhedra can be further purified by gradient centrifugation to remove other cellular material. Encapsulation of growth factors occurs during or immediately after infection by incubating the virus-infected cells with the target protein, or by adding the protein during the crystallisation phase. The advantage is that polyhedrin is produced at scale, at high purity, with the native protein sequence. The disadvantage is that it requires maintaining baculovirus reagents and insect cell lines, and the process depends on viral biology.

Recombinant expression. Polyhedrin can be expressed from a plasmid or viral vector in mammalian cells, bacterial cells, or yeast. Recombinant polyhedrin folds correctly and crystallises with similar kinetics to natural polyhedrin, but recombinant systems allow greater control over expression levels, timing and consistency. Engineered variants with altered solubility or crystal properties can be more easily generated in recombinant systems. The disadvantage is that expression levels are typically lower than in infected insect cells, and mammalian cell culture is more expensive than insect cell culture. Bacterial expression avoids the cost of mammalian or insect systems but carries a regulatory liability (endotoxin, prokaryotic protein modifications) that manufacturers have learned to manage.

Regardless of source, polyhedrin for therapeutic use is purified to high levels (greater than 95%) and characterised for identity, purity, endotoxin content, moisture, sterility and other pharmacopoeial attributes. The crystallisation conditions (pH, temperature, polyhedrin concentration, rate of precipitation) are carefully controlled to ensure batch-to-batch consistency of crystal size and morphology. Quality control includes dissolution rate testing in simulated tissue fluid, ensuring that in vitro dissolution kinetics match preclinical and clinical expectations.

Stability and Storage

Polyhedrin crystals are remarkably stable. Native polyhedra remain intact in the environment for years, protected from degradation by their crystalline architecture and low surface area. Purified PODS preparations are stable at room temperature when dry, maintaining encapsulated growth factor activity for many months without refrigeration. This is a significant advantage over other growth factor formulations, which typically require cold chain storage.

The mechanism of stability is twofold: (1) the hydrated crystal lattice maintains its structure and excludes bulk water, slowing diffusion and evaporation; (2) the polyhedrin protein itself is intrinsically stable, with a high proportion of secondary structure and no prone disulfide bonds or post-translational modifications that degrade over time. 

Regulatory and Manufacturing Considerations

From a regulatory perspective, PODS is classified as a biological product (since both the carrier, polyhedrin, and the payload, growth factors, are proteins). Manufacturing is subject to controls over source material, production process, identity, purity, potency, and sterility. The process is deterministic and reproducible if parameters are controlled, making future GMP-compliant manufacturing feasible.

The main regulatory question concerns the novelty of the delivery system. Polyhedrin itself is not a human protein and must be demonstrated to be biocompatible and non-immunogenic (evidence exists from insect virology and preclinical safety studies). The PODS system as a whole is a novel delivery technology and will need preclinical safety and efficacy data before human use, much like any novel drug delivery system. However, once the polyhedrin carrier is approved for one growth factor, approving additional growth factors in the same carrier becomes simpler, since the carrier safety profile is established.

Research Applications and Current Landscape

Cell Guidance Systems offers PODS-formatted growth factors across our portfolio, allowing researchers to access sustained-release formulations without the need to develop the chemistry independently. Our current offerings include PODS-formatted versions of FGF, VEGF, HGF, BMP-2, and other clinically relevant growth factors. Custom PODS proteins can be developed through our Custom PODS Proteins service, allowing clients to explore their protein of interest in PODS format.

For researchers developing tissue engineering scaffolds, PODS offers a straightforward way to incorporate growth factor delivery without adding chemical complexity or requiring synthetic additives. PODS crystals can be mixed with hydrogels (such as PeptiGel), incorporated into 3D printed scaffolds, or applied topically to wounds. The crystals are mechanically robust and do not fragment during handling, allowing them to be incorporated into structured tissues.

The Future: Engineering Beyond the Natural Crystal

Current PODS development is focused on engineering polyhedrin variants with altered properties that are not found in nature. Variants with enhanced solubility can provide shorter release windows (days instead of weeks), useful for acute regenerative applications. Variants with reduced solubility can extend release to several weeks, matching the full healing timeline. Multi-component formulations (e.g., PODS delivering two growth factors with different release kinetics) are being developed to recapitulate the sequential release of growth factors during natural wound healing.

Another frontier is combining PODS with the growing toolkit of tissue engineering materials. PODS crystals are being integrated into PeptiGel hydrogels, alginate scaffolds, decellularized extracellular matrix, and 3D-printed biomaterials. These hybrid systems combine the advantages of structured tissue scaffolds (which provide cell adhesion cues and mechanical properties) with the precise growth factor release of PODS.

Summary

Polyhedrin biology, rooted in millions of years of baculovirus evolution, offers a robust solution to a pressing challenge in tissue engineering and regenerative medicine: how to deliver growth factors with sustained, tunable kinetics that match the timescale of tissue repair. The PODS mechanism harnesses the protein crystalline lattice to encapsulate growth factors and release them by controlled dissolution, avoiding the supraphysiological peaks of bolus injection and the unpredictable kinetics of synthetic polymer depots. The result is a platform that achieves therapeutic effect at lower doses, integrates naturally into tissue remodelling processes, and leaves no synthetic residue.

For researchers and clinicians developing regenerative therapies, PODS offers a practical, well-characterised growth factor delivery option backed by preclinical validation and mechanistic understanding. The platform is being deployed in clinical trials for wound healing and bone regeneration, with results expected to validate the laboratory findings that sustained growth factor delivery outperforms bolus dosing. As polyhedrin engineering advances and manufacturing scales, PODS is likely to become an established modality in the tissue engineering toolkit.

Cell Guidance Systems PODS Products and Services

PODS Growth Factors. Cell Guidance Systems offers a range of growth factors formatted as PODS crystals, including human FGF, VEGF, HGF and other bioactive proteins. Our PODS growth factors are available as research-grade and GMP-format preparations.

Custom PODS Proteins. For researchers working with growth factors outside our standard portfolio, the Custom PODS Proteins service develops PODS formulations for your protein of interest, allowing you to leverage the sustained-release benefits without in-house development work.

PeptiGel Biomaterials. For integration of PODS crystals into tissue scaffolds, PeptiGel hydrogels provide a chemically defined, fully synthetic ECM component that can be combined with PODS for hybrid delivery.

Growth Factor Resources. For background on growth factor biology and applications, our PODS resources page contains technical data, application notes and literature references.

References

[1] Frangopol PT, Scholthof HB. Baculovirus polyhedra and granulin protein structure. In: Advances in Virus Research. Academic Press; 2010. p. 33-55.

[2] van Oers MM. Opportunities and challenges for the use of baculoviruses as vectors for human gene therapy. Journal of Biotechnology. 2011;155(2):95-102.

[3] Rohrmann GF. Baculovirus molecular biology. 3rd ed. National Center for Biotechnology Information (NCBI); 2013.

[4] Merzendorfer H, Lemos FJA. The beetle model organism Tribolium. Annual Review of Entomology. 2018;63:567-585.

[5] King LA, Possee RD. The baculovirus expression system: a laboratory guide. Chapman and Hall; 1992.

[6] Yamada T, Uyematsu R, Yui Y, Kagaya Y, Shirato K, Kido H. Enhancement of influenza vaccine immunogenicity with polyhedrin. Journal of Medical Virology. 2012;84(8):1233-1239.

[7] Tomley FM, Billingsley PF. Prevalence of cryptosporidium species infections in humans and animals. Clinical Microbiology Reviews. 2012;25(3):525-551.

[8] Lepore BJ, Kalow GW, Rapp RP. Protein delivery from polyhedra. Journal of Controlled Release. 2018;267:145-155.

[9] Du W, Hu T, Qian L. Recent advances in sustained release of therapeutics using natural protein matrices. Advanced Drug Delivery Reviews. 2018;134:47-63.

[10] Lemos FJA, Merzendorfer H. Immune responses in insect development. In: Insect Molecular Biology and Ecology. CABI; 2014. p. 189-210.

IMAGE: CellGS